Ancillary tests for hepatobiliary neoplasms: what we know and what we need to know

被引:2
|
作者
Zhang, Sarah L. [1 ]
Wang, Hanlin L. [2 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA
[2] UCLA, Dept Pathol & Lab Med, David Geffen Sch Med, 10833 Le Conte Ave, Los Angeles, CA 90095 USA
关键词
Hepatocellular carci-noma; Hepatocellular adenoma; Bile duct; Cholangiocarcinoma; Metastatic carcinoma; Biomarker; IN-SITU-HYBRIDIZATION; LINDAU GENE-PRODUCT; C-REACTIVE PROTEIN; DIFFERENTIATING HEPATOCELLULAR-CARCINOMA; CELL NUCLEAR ANTIGEN; INTRAHEPATIC CHOLANGIOCARCINOMA; GLUTAMINE-SYNTHETASE; DIAGNOSTIC UTILITY; BILIARY-TRACT; IMMUNOHISTOCHEMICAL MARKERS;
D O I
10.1016/j.humpath.2023.02.001
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Ancillary tests are commonly used in the surgical pathology setting for diagnosing challenging neoplastic diseases of the liver and biliary tract, while histology and clinical correlation remain to be critically important. With continuous discoveries, more and more useful ancillary tests have become available, which can help distinguish between malignant and benign hepatocellular neoplasms, malignant and benign biliary tract entities, and intrahepatic and metastatic carcinomas. This review will focus on existing and emerging biomarkers (such as glutamine synthetase, organic anion transporting polypeptide 1B3, insulin-like growth factor-II mRNA binding protein-3, S100P, SMAD4, enhancer of zeste homolog 2, albumin, hepatocyte nuclear factor-1b, etc.) that can be used for the diagnosis, classification and prognostication of hepatobiliary neoplasms. (c) 2023 The Author(s). Published by Elsevier Inc.
引用
收藏
页码:183 / 200
页数:18
相关论文
共 50 条
  • [1] Impacts of Neonicotinoids on Molluscs: What We Know and What We Need to Know
    Ewere, Endurance E.
    Reichelt-Brushett, Amanda
    Benkendorff, Kirsten
    TOXICS, 2021, 9 (02) : 1 - 29
  • [2] Yttrium-90 Radioembolization for Hepatocellular Carcinoma: What We Know and What We Need to Know
    Kim, Yun Hwan
    Kim, Do Young
    ONCOLOGY, 2013, 84 : 34 - 39
  • [3] Lp(a): What we know, what we don't know and what we hope for
    Amengual, A. Moya
    Serrano-Cumplido, A.
    MEDICINA DE FAMILIA-SEMERGEN, 2025, 51 (07):
  • [4] Hepatocellular adenoma: what we know, what we do not know, and why it matters
    Bioulac-Sage, Paulette
    Gouw, Annette S. H.
    Balabaud, Charles
    Sempoux, Christine
    HISTOPATHOLOGY, 2022, 80 (06) : 878 - 897
  • [5] Preoperative Hepatobiliary Imaging: What Does the Radiologist Need to Know?
    Wigham, Andrew
    Grant, Lee Alexander
    SEMINARS IN ULTRASOUND CT AND MRI, 2013, 34 (01) : 2 - 17
  • [6] Acute kidney injury in critically ill newborns: What do we know? What do we need to learn?
    Askenazi, David J.
    Ambalavanan, Namasivayam
    Goldstein, Stuart L.
    PEDIATRIC NEPHROLOGY, 2009, 24 (02) : 265 - 274
  • [7] Aberrantly Glycosylated IgA1 in IgA Nephropathy: What We Know and What We Don't Know
    Ohyama, Yukako
    Renfrow, Matthew B.
    Novak, Jan
    Takahashi, Kazuo
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (16)
  • [8] Acute kidney injury in critically ill newborns: What do we know? What do we need to learn?
    David J. Askenazi
    Namasivayam Ambalavanan
    Stuart L. Goldstein
    Pediatric Nephrology, 2009, 24 : 265 - 274
  • [9] ROS in hepatocellular carcinoma: What we know
    Xing, Lin
    Tang, Yuting
    Li, Lu
    Tao, Xufeng
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2023, 744
  • [10] MicroRNAs in inflammatory bowel disease: What do we know and what can we expect?
    De Oliveira, Ellen Cristina Souza
    Quaglio, Ana Elisa Valencise
    Grillo, Thais Gagno
    Di Stasi, Luiz Claudio
    Sassaki, Ligia Yukie
    WORLD JOURNAL OF GASTROENTEROLOGY, 2024, 30 (16) : 2184 - 2190